Vol. 3 No. 12 (2023)
Reimbursement Recommendations

Somapacitan (Sogroya)

Published December 5, 2023

Key Messages

  • CADTH recommends that Sogroya should be reimbursed by public drug plans for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]) if certain conditions are met.
  • Sogroya should only be covered to treat children who are at least 2.5 years of age, have not reached puberty yet, and are diagnosed with GHD.
  • Sogroya should only be reimbursed for a patient who is under the care of a pediatric endocrinologist and whose growth plates have not closed if Sogroya does not cost more than somatropin and somatrogon.